Skip to content
Evigrade
CriticalAntiepileptics. Carboxamide derivatives×Pharmacokinetic enhancer (booster) for antiretroviral therapy

Updated · Methodology

Mechanism

Carbamazepine is a strong inducer of CYP3A4: it speeds up the metabolism of drugs cleared by this enzyme and can lower their levels (carbamazepine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). CYP3A also metabolises cobicistat itself. In a study with elvitegravir and cobicistat, carbamazepine 200 mg twice daily lowered the area under the concentration-time curve (AUC) of cobicistat by 84% and its trough level by 90% (cobicistat SmPC, European Medicines Agency, EMA). Levels of atazanavir or darunavir, the drugs that cobicistat boosts, fall as well, so treatment of human immunodeficiency virus (HIV) infection may stop working and the virus may become resistant (cobicistat SmPC, EMA). In the other direction, cobicistat inhibits CYP3A. In the same study, the AUC of carbamazepine rose by 43%, while the AUC of its active metabolite, carbamazepine-10,11-epoxide, fell by 35% (cobicistat SmPC, EMA, and carbamazepine SmPC, AEMPS).

Symptoms

The main risk is that treatment of human immunodeficiency virus (HIV) infection stops working and the virus becomes resistant (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA). Loss of treatment effect causes no symptoms by itself and is detected by virological testing (cobicistat label, US Food and Drug Administration, FDA). Higher carbamazepine levels may cause dizziness, drowsiness, poor coordination (ataxia) and double vision (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

The combination is contraindicated. Carbamazepine is on the cobicistat contraindication list together with phenobarbital and phenytoin. As strong CYP3A inducers, they lower the levels of cobicistat and of the drug it boosts, and treatment may lose its effect (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and cobicistat label, US Food and Drug Administration, FDA). The same contraindication appears in the SmPCs of the combination tablets with cobicistat: darunavir/cobicistat, atazanavir/cobicistat and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (SmPCs of these products, EMA). For a person taking cobicistat, choose seizure treatment without carbamazepine, phenobarbital or phenytoin (cobicistat SmPC, EMA, and FDA label). Oxcarbazepine and eslicarbazepine also induce CYP3A but are not contraindicated. With them, consider an alternative anticonvulsant or antiretroviral drug. If the combination is necessary, monitor for loss of virologic response (cobicistat FDA label). Before starting cobicistat and during treatment, consider possible interactions, review all concomitant medicines and monitor for their adverse effects (cobicistat FDA label). Carbamazepine can also lower the levels of human immunodeficiency virus (HIV) protease inhibitors and weaken or even cancel their effect (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If carbamazepine and cobicistat have nevertheless been taken together, adjust the carbamazepine dose and/or monitor its blood levels, as with any CYP3A4 inhibitor (carbamazepine SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Carbamazepine

Other interactions with Cobicistat